\n<\/p>\n
Otsuka Pharmaceutical Development & Commercialization, Inc., along with Otsuka Pharmaceutical Co., Ltd., recently shared encouraging findings from their Phase 3 VISIONARY trial. The study focused on VOYXACT (sibeprenlimab-szsi), a treatment for adults with primary IgA nephropathy (IgAN), a kidney condition that can worsen over time. The results indicate that VOYXACT helps stabilize kidney function, preventing the typical decline for up to two years.<\/p>\n
At the GlomCon Hawaii 2026 conference, researchers presented data showing that participants taking VOYXACT had a slight increase in their estimated glomerular filtration rate (eGFR) by +0.3 mL\/min\/1.73 m\u00b2\/year, compared to a decline of -4.2 mL\/min\/1.73 m\u00b2\/year with a placebo. This translates to a significant difference of +4.5, confirming VOYXACT\u2019s positive impact on kidney health.<\/p>\n
Dr. Dana Rizk, a nephrology expert at the University of Alabama at Birmingham, noted that maintaining kidney function represents a significant step forward for managing IgAN. The study met key treatment goals, showing how VOYXACT can fundamentally change the disease’s progression. This, along with a good safety profile, brings hope for improved long-term outcomes for those living with this condition.<\/p>\n
The eGFR measurements were taken regularly throughout the two-year trial, highlighting VOYXACT\u2019s effectiveness. By the end of the study, the average eGFR improvement in patients taking VOYXACT was +1.3 mL\/min\/1.73 m\u00b2, while those on placebo experienced a decline of -7.9 mL\/min\/1.73 m\u00b2.<\/p>\n
John Kraus, Otsuka’s Chief Medical Officer, stated that this trial is the largest of its kind for IgAN, offering significant insights into real-world clinical practice. The results indicate not just symptom management, but a real chance to stabilize kidney function and slow disease progression, potentially transforming treatment options.<\/p>\n
Otsuka expressed gratitude to all patients, families, and researchers involved in the trial, emphasizing the ongoing commitment to advancing IgAN research and finding new solutions for patients.<\/p>\n
VOYXACT is unique as the first U.S. FDA-approved selective APRIL inhibitor, specifically targeting IgAN drivers to change the disease’s course. It received accelerated approval in November 2025, having shown significant improvement in protein levels over a nine-month period. The favorable safety profile of VOYXACT reinforces its potential for long-term use. The latest eGFR findings round out the Phase 3 data, supporting Otsuka\u2019s application for traditional FDA approval. <\/p>\n
This development marks a hopeful chapter in the fight against IgAN and may lead to better treatment options for many patients.<\/p>\n\n","protected":false},"excerpt":{"rendered":"
Otsuka Pharmaceuticals Reports Promising Results for Kidney Treatment Otsuka Pharmaceutical Development & Commercialization, Inc., along with Otsuka Pharmaceutical Co., Ltd., recently shared encouraging findings from their Phase 3 VISIONARY trial. The study focused on VOYXACT (sibeprenlimab-szsi), a treatment for adults with primary IgA nephropathy (IgAN), a kidney condition that can worsen over time. The results<\/p>\n","protected":false},"author":1,"featured_media":39365,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rank_math_lock_modified_date":false,"footnotes":""},"categories":[30],"tags":[51959,50251,10655,3293,51960,51961,51962,51963,647,51964,51965,1839],"class_list":["post-39364","post","type-post","status-publish","format-standard","has-post-thumbnail","category-business-news","tag-biologics","tag-clinicaltrials","tag-fda","tag-healthcare","tag-igan","tag-kidney","tag-nephrology","tag-otsuka","tag-pharmaceuticals","tag-sibeprenlimab","tag-voyxact","tag-wbo"],"_links":{"self":[{"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/posts\/39364","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/comments?post=39364"}],"version-history":[{"count":0,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/posts\/39364\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/media\/39365"}],"wp:attachment":[{"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/media?parent=39364"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/categories?post=39364"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/tags?post=39364"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}